News | August 07, 2024
Gland Pharma posts 16% revenue growth in Q1 FY25
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated
